Koschmieder, Steffen http://orcid.org/0000-0002-1011-8171
Isfort, Susanne http://orcid.org/0000-0002-2855-561X
Schulte, Clemens
Jacobasch, Lutz http://orcid.org/0000-0001-7519-8830
Geer, Thomas
Reiser, Marcel http://orcid.org/0000-0002-0457-7793
Koenigsmann, Michael
Heinrich, Bernhard
Wehmeyer, Jürgen
von der Heyde, Eyck
Tesch, Hans
Gröschl, Benedikt
Bachhuber, Petra
Großer, Susanne
Pahl, Heike L. http://orcid.org/0000-0003-2857-2396
Funding for this research was provided by:
Novartis Pharma
RWTH Aachen University
Article History
Received: 28 July 2023
Accepted: 16 September 2023
First Online: 4 October 2023
Declarations
:
: The study was approved by institutional review boards and independent ethics committees at each center (leading ethics committee: ethics committee at the medical faculty of the University of Aachen) and conducted in accordance with all local legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Patients, Guidelines for Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent at study inclusion.
: Not applicable.
: Steffen Koschmieder reports funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie; patent für BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie; and other financial support (e.g. travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie.Susanne Isfort reports advisory board honoraria from Pfizer, Incyte, and Novartis,honoraria from Novartis, BMS, Pfizer, Incyte, Abbvie, AOP Orphan and other financial support (e.g. travel support) from Alexion, Novartis, Pfizer, Mundipharma, Roche, Hexal and AOP Orphan.Heike Pahl reports advisory board honoraria from Novartis and AOP Pharma.